CareDx
Runs transplant testing, patient tools, and workflow support around organ health.
Something off on this page? Send us feedback.
Profile
Provides molecular surveillance tests for heart, kidney, and lung transplants, supported by patient and digital tools for transplant centers. The business is centered in the US, reports one segment, and is narrowing around testing services plus patient and digital solutions.
Provides precision medicine tools for transplant care, anchored by AlloMap Heart, AlloSure Kidney, AlloSure Heart, HeartCare, and AlloSure Lung. These services monitor rejection or graft injury across heart, kidney, and lung transplant patients.
Adds workflow software, medication-adherence tools, quality tracking, HLA workflow systems, and specialty pharmacy support for transplant centers. Lab products remain part of the portfolio, but a divestiture agreement would shift focus toward testing services and patient and digital solutions.
Operates from a Brisbane, California lab and is concentrated around U.S. transplant centers. Medicare reimbursement, MolDX and Noridian coverage policy, transplant-center adoption, and direct competition from other molecular surveillance providers shape the business.
Company facts
Key statistics
Year to date +160% · Average volume (30d) 1.2M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | BTIG | Reiterate | Buy | $45 | $60 | |
| Aug 3, 2026 | Craig-Hallum | Upgrade | Hold | Buy | $35 | $64 |
| Jul 31, 2026 | H.C. Wainwright | Reiterate | Neutral | $25 | $46 | |
| Jul 16, 2026 | BTIG | Reiterate | Buy | $28 | $45 | |
| Jul 16, 2026 | Craig-Hallum | Reiterate | Hold | $26 | $35 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $0.23 | $0.37 | +59.4% | $114.1M | $131.9M | +15.7% | +14.72% |
| Apr 28, 2026Q1 FY26 | $0.11 | $0.34 | +209.1% | $102.0M | $117.7M | +15.4% | −5.07% |
| Feb 24, 2026Q4 FY25 | $0.02 | $0.12 | +503.0% | $103.3M | $108.4M | +5.0% | −4.10% |
| Nov 4, 2025Q3 FY25 | $0.13 | $0.28 | +115.4% | $102.8M | $100.1M | −2.6% | +13.84% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $84.7M | $86.7M | $100.1M | $108.4M | $117.7M | $131.9M | |
| Gross profit | $56.3M | $58.0M | $69.4M | $72.9M | $84.1M | $97.0M | |
| Operating income | −$8.0M | −$10.8M | −$246.0K | −$6.0M | $1.8M | $257.0K | |
| Net income | −$10.4M | −$8.6M | $1.7M | −$4.1M | $2.8M | $110.6M | |
| Diluted EPS | −$0.19 | −$0.16 | $0.03 | −$0.08 | $0.05 | $2.07 | |
| Gross margin | 66.4% | 66.9% | 69.4% | 67.2% | 71.4% | 73.5% | |
| Operating margin | -9.5% | -12.4% | -0.2% | -5.6% | 1.5% | 0.2% |
Fiscal years (4-quarter sums)FY21 $296.4M · FY22 $321.8M · FY23 $280.3M · FY24 $333.8M · FY25 $379.8M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $373.6M · Total debt $19.2M · Total assets $533.0M · Shareholders' equity $425.6M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 51.73M · Float 49.32M · 95.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.81M | 9.31% | 13F | Aug 7, 2026 |
| State Street Corp | 2.47M | 4.77% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 2.20M | 4.25% | 13F | Aug 13, 2026 |
| Deerfield Management Company, L.P. (Series C) | 2.00M | 3.86% | 13F | Aug 14, 2026 |
| Ark Investment Management LLC | 1.95M | 3.78% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 4, 2026 | Michael Goldberg | director | −44,700 | $47.06 |
| Aug 5, 2026 | Jeffrey Adam Novack | officer: Secretary and General Counsel | −2,688 | $46.26 |
| Aug 4, 2026 | Christine Cournoyer | director | −16,000 | $46.94 |
| Aug 5, 2026 | George Bickerstaff | director | −20,000 | $46.29 |
| Jul 16, 2026 | Hannah Valantine | director | −28,779 | $36.15 |
Peers
- Natera
Closest public rival in transplant dd-cfDNA surveillance
- Insight Molecular Diagnostics
Micro-cap public rival in dd-cfDNA transplant testing
- Thermo Fisher Scientific
One Lambda leads HLA typing and transplant lab products
- QIAGEN
NGS and sample-to-insight tools overlap in HLA typing
- Bio-Rad Laboratories
Clinical-diagnostics tools touch transplant lab workflows
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CareDx | $49.72 | −0.12% | $2.58B | 24.0 | 42.9 | 5.6 | +52.2% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Insight Molecular Diagnostics | $4.13 | 0.00% | $133.4M | — | — | 79.9 | −53.9% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| QIAGEN | $43.00 | −0.28% | $8.89B | 22.1 | 17.3 | 4.2 | +0.3% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| Median | 33.5 | 23.7 | 5.0 | +0.3% |